Urogen Pharma (URGN) Posts Fourth Quarter Loss, Surpasses Revenue Projections

Urogen Pharma (URGN) Reports Smaller-Than-Expected Quarterly Loss

Urogen Pharma (URGN) posted a quarterly loss of $0.54 per share, which was narrower than the Zacks Consensus Estimate predicting a $0.66 loss. In comparison, the company reported a loss of $0.80 per share in the same period last year. These results exclude one-time items.

This quarter's performance resulted in a positive earnings surprise of 18.18%. In the previous quarter, Urogen Pharma was anticipated to report a $0.72 per share loss but actually reported a $0.69 loss, beating expectations by 4.17%.

Looking at the past four quarters, Urogen Pharma has exceeded consensus earnings per share estimates twice.

Revenue Performance and Industry Context

Operating within the Medical - Biomedical and Genetics sector, Urogen Pharma generated $37.84 million in revenue for the quarter ending December 2025, surpassing the consensus estimate by 6.42%. This marks a significant increase from the $24.57 million reported a year earlier. However, the company has only exceeded revenue expectations once in the last four quarters.

The direction of Urogen Pharma’s stock price in the near term will likely be influenced by management’s insights during the earnings call, as well as future earnings projections.

Since the start of the year, Urogen Pharma shares have declined approximately 7.3%, while the S&P 500 has edged up by 0.5%.

What Lies Ahead for Urogen Pharma?

Despite underperforming the broader market so far this year, investors are now considering what the future holds for Urogen Pharma stock.

One key factor for investors is the company’s earnings outlook, which includes both current consensus estimates for upcoming quarters and any recent changes to those forecasts.

Research indicates a strong link between short-term stock price movements and trends in earnings estimate revisions. Investors can monitor these changes themselves or use tools like the Zacks Rank, which has a strong track record of leveraging earnings estimate trends.

Prior to this earnings announcement, analyst estimate revisions for Urogen Pharma were mixed. With the latest results now available, these estimates may shift, but the current outlook gives the stock a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the market in the near term.

It will be important to watch how estimates for the next quarters and the current fiscal year evolve. At present, the consensus forecast is for a loss of $0.58 per share on $42.73 million in revenue next quarter, and a loss of $1.13 per share on $250.54 million in revenue for the full year.

Industry Overview and Peer Comparison

Investors should also consider the broader industry outlook, as it can significantly impact individual stock performance. The Medical - Biomedical and Genetics industry currently ranks in the top 36% of over 250 Zacks industries. Historically, the top half of Zacks-ranked industries outperform the bottom half by more than two to one.

Another company in the same sector, Caribou Biosciences, Inc. (CRBU), has not yet released its results for the quarter ending December 2025. Analysts expect Caribou to report a quarterly loss of $0.33 per share, reflecting a 15.4% improvement year-over-year. The consensus estimate for Caribou’s EPS has remained steady over the past month, and its revenue is projected to reach $2.53 million, up 21.4% from the prior year’s quarter.

Is Urogen Pharma (URGN) a Good Investment?

Before deciding whether to invest in Urogen Pharma (URGN), you may want to explore the top stock picks for the next 30 days. Zacks Investment Research offers a complimentary report on the 7 best stocks to buy now.

Since 1978, Zacks Investment Research has provided investors with independent analysis and tools. Over the past 25 years, the Zacks Rank stock-rating system has delivered an average annual return of 24.08%, more than doubling the S&P 500’s performance from January 1, 1988, through May 6, 2024.

For the latest stock recommendations from Zacks Investment Research, you can download the 7 Best Stocks for the Next 30 Days.